Work

Pyridoxamine does not reduce arterial stiffness in an 8‐week randomized double‐blind placebo‐controlled intervention trial with abdominally obese individuals

Year: 2025
Type: article
Abstract: Arterial stiffening is associated with cardiovascular disease (CVD).Several studies suggest an association of arterial stiffness with advanced glycation end products (AGEs).1,2 The accumulation of AGEs in long-lived proteins such as collagen may lead to cross-linking and possibly to increased arterial stiffness.The dicarbonyl compound methylglyoxal (MGO), a reactive metabolite mainly formed as a byproduct of glycolysis, is the major precursor in the formation of AGEs.MGO levels are elevated in obesity and MGO has been associated with the development of many age-related complications 3 and incident CVD in diabetes.4,5 Pyridoxamine (PM), a B6 vitamer and scavenger of MGO, was able to reduce diabetes-induced artery calcification 6 and was able to prevent aortic stiffening in rat and old mouse models.[7][8][9] We recently showed that PM prevents vascular dysfunction in mice.10 These findings suggest the role of PM in reducing arterial stiffening by targeting the formation of MGO stress and AGE-induced collagen cross-linking.In an RCT with abdominally obese individuals, we recently demonstrated a reduction in MGO and endothelial dysfunction markers by 8 weeks of PM supplementation.11 In this post-hoc analysis of the RCT study, we aim to investigate the effects of this 8 week PM supplementation on arterial stiffness. | MATERIALS AND METHODSApparently, healthy individuals with abdominal obesity (54% female; mean age 50 years; mean body mass index 32 kg/m 2 ) were randomized to an 8-week intervention with either placebo (n = 36), a low dose of 25 mg PM (n = 36) or a high dose of 200 mg PM (n = 36).
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,380
OpenAlex ID: W4411282916
FWCI: 1.682
Cites: 14
Cited by: 3
Related to: 10